Abstract: This invention relates to a method for modulating, inhibiting or decreasing or preventing beta cell degeneration, loss of beta cell function, beta cell dysfunction, and/or death of beta cells, such as necrosis or apoptosis of beta cells in a subject comprising administering a GLP-1 agonist to said subject.

Abstract: By a cylinder ampoule (1), comprising a tubular vessel with a membrane (4) sealingly closing one end and a piston (9) closing the other end, liquid stored between said piston (9) and said membrane (4) can be pressed out through an injection needle (7) piercing the membrane (4) when the piston (9) is pressed into the ampoule (1). The tube is made from a plastically deformable material. A pressure foot (10) on which a piston rod (13) is acting abuts the piston (9), carries a spring plate (11) made from a harder material than is the ampoule (1), is mainly perpendicular to the ampoule (1) axis, and has at least one diameter which is larger than the inner diameter of the ampoule (1) so that edges of the plate (11) abutting the inner wall of the ampoule (1) are deflected away from the piston (9) to form an acute angle with said wall.

Abstract: The present invention relates to compounds of formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

Abstract: The present invention relates to novel N-substituted azaheterocyclic compounds of the general formula wherein X, Y, Z, A, R1, R2, r and s are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for treatment of indications caused by or related to secretion and circulation of insulin antagonising peptides.

Abstract: This invention relates to novel compounds, compositions containing them, and their use for treating medical disorders resulting from a deficiency in growth hormone.

Abstract: A readily-soluble freeze-dried solid preparation of hGH with a minimal content of degradation products in terms of deamidation, dimers, polymers, and sulphoxide forms, obtainable by a method comprising a single lyophilization of an aqueous slurry of an amorphous hGH isoprecipitate, the slurry having a pH of from about 4.7 to 5.0 and being essentially free of buffer components other than acetate.

Abstract: Disclosed is a method for producing seeding microcrystals for the production of human insulin, the microcrystals being free of non-human pancreatic insulin, the method comprising providing an unseeded suspension of human insulin, the suspension being free of non-human pancreatic insulin, and homogenizing the insulin suspension under pressure to result in human insulin microcrystals suitable for use as seeding microcrystals for the production of zinc insulin products. The method of homogenization under pressure may also be used for the production of seeding mnicrocrystals for other peptides and proteins, in particular pharmaceutical peptides or proteins such as insulin, GLP-1, glucagon and growth hormones.

Abstract: A novel class of compounds, which act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor the compounds may be suitable for the treatment and/or prevention of any diseases and disorders, wherein a glucagon antagonistic action is beneficial, such as hyperglycemia, Type 1 diabetes, Type 2 diabetes, disorders of the lipid metabolism, such as dyslipidemia, and obesity.

Abstract: The present invention relates to a medication delivery device comprising a cartridge assembly, a dosing assembly and optionally a needle assembly. The cartridge assembly comprises a cartridge having a stopper adapted to receive a plunger means. Furthermore, the cartridge assembly has one end sealed with a pierceable sealing, said end comprising coupling means for engaging a needle assembly, and another end comprising coupling means for engaging the dosing assembly. At least one of the coupling means of the cartridge assembly is unitarily moulded with the cartridge. The dosing assembly comprises a plunger means and has coupling means for engaging the cartridge assembly. The cartridge assembly and the dosing assembly are coupled together for delivering selected doses of medication. The cartridge is preferably moulded from a plastic material, such as a transparent material, and may be housed in a cartridge housing for protection of the cartridge.

Abstract: Compounds of peptide mimetic nature having the general formula I wherein a and b are independently 1 or 2, R1 and R2 are independently H or C1-6alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.

Abstract: Analysis of full-blood glucose, serum insulin, serum triglycerides and total serum cholesterol were performed. Glucose levels in blood samples from the oral glucose tolerance test were used for calculation of the incremental Area Under the Curve (AUC0-120 min−baseline). All data are expressed as percentage change of vehicle treated animals (cf. FIGS. 1 and 2).

Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

Abstract: A disposable double pointed injection needle has a needle hub to which a thin needle cannula is permanently fasten and which needle hub can be mounted on to a syringe comprising a dose setting and injection mechanism and a cartridge containing a liquid medicine to be injected subcutaneously into a human body. The needle hub is provided with a safety shield guided on the outside surface of the needle hub. The safety shield is urged in a direction away from the needle hub by a spring located between the needle hub and the safety shield. The safety shield has a number of protrusions guided in guiding tracks on the outside surface of the needle hub. The guiding tracks are designed such that the safety shield during injection is moved towards the needle hub, and after injection is moved away from the needle hub by the spring and locked in an irreversible position where the safety shield covers the needle cannula and prevents accidental needle stick injuries.

Abstract: A dose display for a medicine administration device in which rotation of a dose setting actuator (22) is transmitted to a display means comprises a flexible disc (23) carrying numbers in a band along its perimeter, which numbers are in accordance with the set dose presented in a window in a wall of the device to show said dose. During its rotation the disc (23) is deflected to follow an inner contour of the device to attain a cylindrical shape having a generatrix extending in the axial direction of the injection device and perpendicular to the axis of rotation of the disc.

Abstract: Human infertility can be treated by in vitro methods that actively arrest the human oocyte in prophase of first meiotic division and subsequently actively reverse this meiotic blockage by either adding at least one meiosis-stimulating compound or by culture conditions leading to endogenous formation of meiotic stimulating molecules in the oocyte-cumulus complex.

Abstract: This invention relates to an system for self treatment. The system consists of several portable modules where one of the modules is designated as a master module. The master module controls, supervises and monitors all the mutual information and data exchange between itself and the rest of the modules. The modules can e.g. consist of a BGM, a doser, an inhaler, a tablet dispenser and a storage container. The modules may be able to generate and store data which is transmitted to the master module if it is within range and active. If the master module is not within range, the data is kept locally in the module until the master module is available or a new master module is designated. The master module or another specific module can send the data to an external unit like a computer or database for further processing. A physician or an expert care-team can access the data in the database and give guidance to the patient on the basis of these processed data.

Abstract: The invention relates to: A portable medication delivery device (1) comprising a medication cartridge (11) having an outlet (111) and a movable piston (112), and a housing (12) for holding said cartridge, and a flexible piston rod (13) being operable to engage and displace said piston along an axis (113) of said cartridge, and guiding means (14) for bending said piston rod away from said axis, and actuating means (15), and driving means (16, 17) for transferring movement from said actuating means to said piston rod, said driving means including a driving wheel (17) for displacing the piston rod (13), said flexible piston rod comprising regularly spaced first members (330; 331; 332) adapted to mechanically cooperate with corresponding second members (171) on said driving wheel. The object of the present invention is to provide a medication delivery system that combines compactness with an improved accuracy.

Abstract: An automatic needle insertion device for a pen shaped syringe comprising a cartridge holder (2) wherein a cartridge with a drug can be accommodated, and a dose setting and injection part (1) by which a wanted dose may be set an subsequently pressed out from the cartridge by pressing a button (12) projecting from the dose setting and injection part (1). The device comprises a mainly tubular housing (31) in which a tubular pen holder (22) in which a pen can be mounted can be axially displaced in a proximal direction to cock a spring (30) which can thereafter be released to drive the pen holder (22) with the pen a set distance in a distal direction.

Abstract: The present invention relates to compounds of the general formula (I) The compounds are useful in the treatment and/or prevention of conditions mediated by nuclear receptors, in particular the Peroxisome Proliferator-Activated Receptors (PPAR).

Abstract: A cartridge (1) for an injection device carries a code represented by a number of bars (2, 3, 4, 5) mainly perpendicular to the axis of the cartridge. The bars (2, 3, 4, 5) are mainly transparent and are each along its whole length provided with an optical grating which diffracts and reflects light impinging the surface carrying the code so that a minor part of this light is reflected from the surface of the bar as a set of light beams of which beams at least one is detected for the indication of the presence of the bar when said bar passes a reading light field. The reflections from the bars may be interpreted as representing “1”s and “0”s in a binary code.